Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients

NCT00383708 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

125

Enrollment

INDUSTRY

Sponsor class

Conditions

Acromegaly

Interventions

DRUG: lanreotide (Autogel formulation)
DRUG: Pegvisomant

Sponsor

Ipsen